Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

Journal of the National Cancer Institute
A L SabichiM J Birrer

Abstract

The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4HPR) can inhibit the growth of tumor cells. Preliminary results from a clinical trial suggest that 4HPR may reduce ovarian cancer incidence. We examined the growth-inhibitory effects of 4HPR on gynecologic cancer cell lines in vitro and the role of retinoid receptors in modulating this effect. Twelve human gynecologic cancer cell lines (the ovarian cell lines--A224, AD10, UCI 101, UCI 107, SKOV3, 222, CP70, ML3B, and ML5; the cervical cell lines--HT3 and ME180; and the endometrial cell line--Hec 1A were tested for sensitivity to 4HPR (by assaying cell proliferation rates). Gel electrophoretic analysis of DNA fragmentation was used to measure programmed cell death (apoptosis). Specific retinoid receptor (retinoic acid receptor [RAR] and retinoid X receptor) messenger RNA (mRNA) levels were measured by northern blot hybridization. AD10 cells were stably transfected with human RARbeta complementary DNA, and the effect of 4HPR on cell proliferation was examined. 4HPR inhibited the growth of all 12 cell lines, but to varying degrees; IC50 values (i.e., concentrations that inhibit proliferation by 50%) ranged from 0.3 to 9 microM. Following 4HPR treatment, ovarian cancer cells t...Continue Reading

References

Jan 1, 1991·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·R Lotan, J L Clifford
May 26, 1991·The New England Journal of Medicine·R P WarrellA Jakubowski
Sep 20, 1990·The New England Journal of Medicine·W K HongL J Peters
Nov 15, 1995·Journal of the National Cancer Institute·G P KalemkerianM Mabry
Jan 1, 1995·Advances in Pharmacology·H R NaikK J Pienta
Jan 18, 1995·Journal of the National Cancer Institute·G De PaloA Costa
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F FormelliU Veronesi
Jan 21, 1993·International Journal of Cancer. Journal International Du Cancer·D LuceM Goldberg
Feb 8, 1996·International Journal of Cancer. Journal International Du Cancer·R SupinoF Formelli
Sep 13, 1996·The Journal of Biological Chemistry·A N FanjulM Pfahl
Jul 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·F FormelliJ A Olson
Jan 1, 1997·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo
Mar 4, 1997·International Journal of Cancer. Journal International Du Cancer·S TomaW Bollag

❮ Previous
Next ❯

Citations

Aug 15, 2000·Journal of Cellular Physiology·D ZhangK J Soprano
Sep 28, 2002·International Journal of Cancer. Journal International Du Cancer·Yuhe XiaHenk Tideman
Mar 8, 2006·Cancer Chemotherapy and Pharmacology·Bo YangQiaojun He
Jul 20, 2006·Apoptosis : an International Journal on Programmed Cell Death·N HailR Lotan
Apr 21, 2010·Cancer Metastasis Reviews·Andrea TinelliVito Lorusso
Apr 25, 2012·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Eyou WangTongzu Liu
Dec 21, 2000·Current Oncology Reports·R Torrisi, A Decensi
Oct 8, 2003·Gynecologic Oncology·Francesmary Modugno, UNKNOWN Ovarian Cancer and High-Risk Women Symposium Presenters
Nov 8, 2001·International Journal of Radiation Oncology, Biology, Physics·S RyuJ H Kim
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F Formelli, L Cleris
Apr 27, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Wei HuJ J Kavanagh
May 18, 2000·Journal of the National Cancer Institute·M WidschwendterC Marth
Apr 5, 2001·Journal of the National Cancer Institute·U Veronesi, A Decensi
Apr 9, 2010·Pigment Cell & Melanoma Research·Jun FanRichard M Niles
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·K M SommerK Swisshelm
Oct 31, 2003·Expert Opinion on Investigational Drugs·Winfred MaloneHoward Higley
Nov 4, 2008·Addictive Behaviors·Michael S BusinelleDavid W Wetter
Apr 26, 2007·Journal of Clinical Psychology·Monica S WebbFrankie B Quarles
Nov 1, 2007·Journal of Clinical Psychology·Monica S WebbFrankie B Quarles
Jun 25, 2002·Gynecologic Oncology·Giuseppe De PaloUmberto Veronesi
Mar 29, 2002·Environmental and Molecular Mutagenesis·JoAnne Zujewski
Dec 3, 2003·Cell Death and Differentiation·V AppiertoF Formelli
Jan 22, 2004·International Journal of Cancer. Journal International Du Cancer·Hye-Sook HanSoo-Jong Um
Mar 25, 2004·Journal of Cellular Physiology·Scott VuocoloKenneth J Soprano
Apr 18, 2002·Leukemia·J A Fontana, A K Rishi
Jan 28, 2003·Cancer·Judith Clancy Keen, Nancy E Davidson
Jul 4, 2001·Drugs·R TorrisiG De Palo
Mar 30, 2006·International Journal of Cancer. Journal International Du Cancer·Molly BrewerChangping Zou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A DecensiA Polizzi
© 2022 Meta ULC. All rights reserved